Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1287542

registered interest
date	19/02/2021
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Manufacturing Industries: Leicester
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, how many garment factories in Leicester have failed a covid-19 inspection conducted by the Health and Safety Executive.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	155468
answer	answer is ministerial correction date of answer 01/03/2021 answer text <p>HSE have carried out 296 Covid19 specific interventions in respect of textile factories, in Leicester, since April 2020. Premises do not pass and fail, as such, however we can confirm that enforcement action has been taken in respect of 54 premises. Action taken includes a mixture of enforcement notices and letters, in addition to written advice, which were follow up to ensure compliance.</p><p /><p /> <p /><p /> answering member constituency Mid Sussex answering member printed Mims Davies question first answered 01/03/2021 17:02:57 answering member 4513 label Biography information for Mims Davies
tabling member	4848 label Biography information for Claudia Webbe

1287543

registered interest
date	19/02/2021
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Manufacturing Industries: Leicester
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, what powers the Health and Safety Executive has to investigate factories in Leicester where the failure to implement covid-19 safety measures is a serious risk to public health.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	155469
answer	answer is ministerial correction date of answer 01/03/2021 answer text <p>Under Section 20 of the Health and Safety at Work etc. Act 1974, HSE Inspectors have a range of powers that they can use to investigate reported incidents and concerns, including those relating to implementation of Covid 19 safety measures in factories in Leicester.</p><p> </p><p>Inspectors have the right to enter premises to carry out their functions at any reasonable time. They have the right to ask questions, to examine documents and to take copies. They also have the right to talk to employees and safety representatives, as required.</p><p> </p><p>Inspectors have the power to issue Improvement Notices where they identify a breach of health and safety legislation or to issue Prohibition Notices where they identify a risk of serious personal injury. They also have powers to institute proceedings in Court where there has been a serious breach of health and safety legislation.</p><p> </p><p>Throughout the pandemic, HSE has actively engaged with businesses, through site visits and phone calls, investigating reports from those raising concerns, assessing compliance with health and safety law, and using guidance such as that published about social distancing from the Department for Business, Energy and Industrial Strategy (<a href="https://www.gov.uk/guidance/working-safely-during-coronavirus-covid-19" target="_blank">https://www.gov.uk/guidance/working-safely-during-coronavirus-covid-19</a>) to ensure businesses are adhering to requirements. HSE has also provided support to local public health bodies who lead on dealing with outbreaks.</p><p> </p><p>HSE continues to regulate in areas of highest risk and industries where concerns of Covid-19 transmission are greatest.</p> answering member constituency Mid Sussex answering member printed Mims Davies question first answered 01/03/2021 17:10:24 answering member 4513 label Biography information for Mims Davies
tabling member	4848 label Biography information for Claudia Webbe

1287544

registered interest
date	19/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of care home (a) residents and (b) staff have been (i) offered and (ii) refused each vaccine dose in care homes in (A) Leicester East constituency, (B) Leicester and (C) the UK.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	155470
answer	answer is ministerial correction date of answer 17/03/2021 answer text <p>The information requested is not collected centrally.</p><p> </p><p>Published data for England from 4 March shows that as at 28 February, 93.8% of eligible care home residents and 72.9% of eligible care home staff had received their first dose of the COVID-19 vaccine. The proportion of care home residents and staff who have received their second dose is not yet available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 17/03/2021 12:55:00 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4848 label Biography information for Claudia Webbe

1287545

registered interest
date	19/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of NHS staff in each ethnic group in Leicestershire, Leicester and Rutland have been offered the covid-19 vaccine; and how many of those people have (a) refused and (b) not yet taken up the vaccine.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	155471
answer	answer is ministerial correction date of answer 01/03/2021 answer text <p>The information is not currently held in the format requested.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 01/03/2021 17:53:07 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4848 label Biography information for Claudia Webbe

1286576

registered interest
date	11/02/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Saudi Arabia: Political Prisoners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what discussions he has had with US counterpart on encouraging Saudi Arabia to (a) release and lift restrictions on Loujain Alhathloul and other women's rights activists and (b) release Prince Turki Bin Abdullah and other political detainees.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	153419
answer	answer is ministerial correction date of answer 23/02/2021 answer text <p>The Foreign Secretary raised a number of human rights issues including the detention of women's rights defenders, during his visit to Saudi Arabia in March 2020. FCDO Ministers and senior officials also regularly raise human rights with the Saudi authorities. We continue to monitor the cases of Women's rights defenders; and Prince Turki bin Abdullah and Prince Mohammed Bin Nayef. We have consistently pressed for due process and raised concerns about the use of solitary confinement, lack of family contact and allegations of torture, and were pleased to see Loujain Al Hathloul reunited with her family on 10 February.</p><p>The UK regularly engages international partners on human rights. For example, in September, the UK, alongside international partners, signed a statement at the UN Human Rights Council expressing concern over the use of arbitrary detention and calling for the release of all political detainees. In November, the UK Ambassador for Human Rights and six European counterparts released a joint statement reiterating our call for the release of all political detainees.</p> answering member constituency Braintree answering member printed James Cleverly grouped question UIN 153420 question first answered 23/02/2021 15:37:00 answering member 4366 label Biography information for James Cleverly
tabling member	4848 label Biography information for Claudia Webbe

1286577

registered interest
date	11/02/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Saudi Arabia: Political Prisoners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, when he last had discussions with his (a) Saudi counterpart and (b) European counterparts on the cases of (i) Prince Turki Bin Abdullah, (ii) Prince Mohammed Bin Nayef and (iii) other political detainees and women’s rights activists denied fair trials.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	153420
answer	answer is ministerial correction date of answer 23/02/2021 answer text <p>The Foreign Secretary raised a number of human rights issues including the detention of women's rights defenders, during his visit to Saudi Arabia in March 2020. FCDO Ministers and senior officials also regularly raise human rights with the Saudi authorities. We continue to monitor the cases of Women's rights defenders; and Prince Turki bin Abdullah and Prince Mohammed Bin Nayef. We have consistently pressed for due process and raised concerns about the use of solitary confinement, lack of family contact and allegations of torture, and were pleased to see Loujain Al Hathloul reunited with her family on 10 February.</p><p>The UK regularly engages international partners on human rights. For example, in September, the UK, alongside international partners, signed a statement at the UN Human Rights Council expressing concern over the use of arbitrary detention and calling for the release of all political detainees. In November, the UK Ambassador for Human Rights and six European counterparts released a joint statement reiterating our call for the release of all political detainees.</p> answering member constituency Braintree answering member printed James Cleverly grouped question UIN 153419 question first answered 23/02/2021 15:37:00 answering member 4366 label Biography information for James Cleverly
tabling member	4848 label Biography information for Claudia Webbe

1283466

registered interest
date	03/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish all evidence, minutes and documents relating to the decision not to implement Pfizer's recommendation that the two doses of the Pfizer/BioNTech covid-19 vaccine be administered within three weeks.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	148948
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>A phase three clinical trial study on the Pfizer-BioNTech COVID-19 vaccine efficacy demonstrated a two-dose vaccine efficacy of 95% with a second dose delivered between 19 and 42 days.</p><p>Using data available from this study, Public Health England estimated that short term vaccine efficacy from the first dose of the Pfizer-BioNTech vaccine to be approximately 89%. This is the efficacy calculated 15 to 21 days after the first dose. The estimate for 15 to 28 days is 91% which includes the seven days after the second dose and is prior to the time protection may be expected from the second dose.</p><p>There is no estimate of efficacy for a single dose beyond 21 days. Given the data available, evidence on the AstraZeneca COVID-19 vaccine and from the use of many other non-COVID-19 vaccines, the Joint Committee on Vaccination and Immunisation (JCVI) advises a maximum interval between the first and second doses of 12 weeks. The use of ‘short-term’ in this report refers to the impact of the programme over the first months of the programme. Further information on the estimates of efficacy of one dose is available in the JCVI’s statement on 31 December which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact</a></p><p>The British Medical Association have questioned the decision to use an extended schedule for COVID-19 vaccines. Data on the AstraZeneca vaccine indicate better immune responses from the second dose with an extended schedule and that protection is maintained over a twelve-week period.</p><p>The JCVI is of the view that the first dose of the Pfizer-BioNTech vaccine is likely to provide protection for at least 12 weeks.</p><p>There is no evidence to indicate a correlation between the presence of neutralising antibodies and a vaccine effect on transmission.</p><p>The JCVI aims to publish background documents to its meetings. However many of these relating to vaccine efficacy were provided to the committee in confidence or under a non-disclosure agreement and cannot be published by the JCVI. Evidence on vaccine immunogenicity and efficacy will be published by the relevant industry groups, usually in peer reviewed journals.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 148950 148951 148952 148955 148956 148957 148958 question first answered 15/02/2021 09:26:19 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4848 label Biography information for Claudia Webbe

1283467

registered interest
date	03/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish all his communications with the Joint Committee on Vaccination and Immunisation on the decision to extend the maximum wait to receive the second dose of the Pfizer-BioNTech covid-19 vaccine to 12 weeks.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	148949
answer	answer is ministerial correction date of answer 27/04/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) are independent and advise the Secretary of State for Health and Social Care through published statements and letters on GOV.UK. The Secretary of State’s acceptance of their advice is also published on GOV.UK.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/04/2021 10:52:42 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4848 label Biography information for Claudia Webbe

1283468

registered interest
date	03/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the scientific basis was to inform the decision that one dose of the Pfizer/BioNTech COVID-19 vaccine produces enough neutralising antibodies to protect against the covid-19 virus and reduce transmission.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	148950
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>A phase three clinical trial study on the Pfizer-BioNTech COVID-19 vaccine efficacy demonstrated a two-dose vaccine efficacy of 95% with a second dose delivered between 19 and 42 days.</p><p>Using data available from this study, Public Health England estimated that short term vaccine efficacy from the first dose of the Pfizer-BioNTech vaccine to be approximately 89%. This is the efficacy calculated 15 to 21 days after the first dose. The estimate for 15 to 28 days is 91% which includes the seven days after the second dose and is prior to the time protection may be expected from the second dose.</p><p>There is no estimate of efficacy for a single dose beyond 21 days. Given the data available, evidence on the AstraZeneca COVID-19 vaccine and from the use of many other non-COVID-19 vaccines, the Joint Committee on Vaccination and Immunisation (JCVI) advises a maximum interval between the first and second doses of 12 weeks. The use of ‘short-term’ in this report refers to the impact of the programme over the first months of the programme. Further information on the estimates of efficacy of one dose is available in the JCVI’s statement on 31 December which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact</a></p><p>The British Medical Association have questioned the decision to use an extended schedule for COVID-19 vaccines. Data on the AstraZeneca vaccine indicate better immune responses from the second dose with an extended schedule and that protection is maintained over a twelve-week period.</p><p>The JCVI is of the view that the first dose of the Pfizer-BioNTech vaccine is likely to provide protection for at least 12 weeks.</p><p>There is no evidence to indicate a correlation between the presence of neutralising antibodies and a vaccine effect on transmission.</p><p>The JCVI aims to publish background documents to its meetings. However many of these relating to vaccine efficacy were provided to the committee in confidence or under a non-disclosure agreement and cannot be published by the JCVI. Evidence on vaccine immunogenicity and efficacy will be published by the relevant industry groups, usually in peer reviewed journals.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 148948 148951 148952 148955 148956 148957 148958 question first answered 15/02/2021 09:26:19 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4848 label Biography information for Claudia Webbe

1283469

registered interest
date	03/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the validity of the British Medical Association’s reported concerns on the 12-week wait for the second dose of the Pfizer-BioNTech covid-19 vaccine.
tabling member constituency	Leicester East
tabling member printed	Claudia Webbe
uin	148951
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>A phase three clinical trial study on the Pfizer-BioNTech COVID-19 vaccine efficacy demonstrated a two-dose vaccine efficacy of 95% with a second dose delivered between 19 and 42 days.</p><p>Using data available from this study, Public Health England estimated that short term vaccine efficacy from the first dose of the Pfizer-BioNTech vaccine to be approximately 89%. This is the efficacy calculated 15 to 21 days after the first dose. The estimate for 15 to 28 days is 91% which includes the seven days after the second dose and is prior to the time protection may be expected from the second dose.</p><p>There is no estimate of efficacy for a single dose beyond 21 days. Given the data available, evidence on the AstraZeneca COVID-19 vaccine and from the use of many other non-COVID-19 vaccines, the Joint Committee on Vaccination and Immunisation (JCVI) advises a maximum interval between the first and second doses of 12 weeks. The use of ‘short-term’ in this report refers to the impact of the programme over the first months of the programme. Further information on the estimates of efficacy of one dose is available in the JCVI’s statement on 31 December which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact" target="_blank">https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact</a></p><p>The British Medical Association have questioned the decision to use an extended schedule for COVID-19 vaccines. Data on the AstraZeneca vaccine indicate better immune responses from the second dose with an extended schedule and that protection is maintained over a twelve-week period.</p><p>The JCVI is of the view that the first dose of the Pfizer-BioNTech vaccine is likely to provide protection for at least 12 weeks.</p><p>There is no evidence to indicate a correlation between the presence of neutralising antibodies and a vaccine effect on transmission.</p><p>The JCVI aims to publish background documents to its meetings. However many of these relating to vaccine efficacy were provided to the committee in confidence or under a non-disclosure agreement and cannot be published by the JCVI. Evidence on vaccine immunogenicity and efficacy will be published by the relevant industry groups, usually in peer reviewed journals.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 148948 148950 148952 148955 148956 148957 148958 question first answered 15/02/2021 09:26:19 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4848 label Biography information for Claudia Webbe